1-3 of 3
Min Zhu
Close
Sort by
Journal Articles

Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study

Clinical Trials & Observations
Li-Juan Deng, Ke-Shu Zhou, Li-Hong Liu, Ming-Zhi Zhang, Zhi-Ming Li, Chun-Yan Ji, Wei Xu, Ting Liu, Bing Xu, Xin Wang, Su-Jun Gao, Hui-Lai Zhang, Yu Hu, Yan Li, Ying Cheng, Hai-Yan Yang, Jun-Ning Cao, Zun-Min Zhu, Jian-Da Hu, Wei Zhang, Hong-Mei Jing, Kai-Yang Ding, Xiang-Yang Zhang, Ren-Bin Zhao, Bin Zhang, Ya-Min Tian, Yong-Ping Song, Yu-Qin Song, Jun Zhu
Journal: Blood Advances
Blood Adv (2023) 7 (16): 4349–4357.
https://doi.org/10.1182/bloodadvances.2022009168
Published: 2023
Includes: Supplemental data
Journal Articles

Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia

Clinical Trials & Observations
Harry P. Erba, Pamela S. Becker, Paul J. Shami, Michael R. Grunwald, Donna L. Flesher, Min Zhu, Erik Rasmussen, Haby A. Henary, Abraham A. Anderson, Eunice S. Wang
Journal: Blood Advances
Blood Adv (2019) 3 (13): 1939–1949.
https://doi.org/10.1182/bloodadvances.2019030916
Published: 2019
Journal Articles

Analysis of MCFD2- and LMAN1-deficient mice demonstrates distinct functions in vivo

Min Zhu, Chunlei Zheng, Wei Wei, Lesley Everett, David Ginsburg, Bin Zhang
Journal: Blood Advances
Blood Adv (2018) 2 (9): 1014–1021.
https://doi.org/10.1182/bloodadvances.2018018317
Published: 2018